Mixed-Phenotype Acute Leukemia : Diagnostic Criteria and Pitfalls
Mixed-phenotype acute leukemia (MPAL) is a heterogeneous category in the World Health Organization classification that comprises acute leukemias with discrete admixed populations of myeloid and lymphoid blasts ("bilineal") or with extensive coexpression of lymphoid and myeloid markers in a single blast population ("biphenotypic"). Flow cytometric findings suggestive of MPAL are often met with consternation by pathologists and oncologists alike, owing to unfamiliarity with the disease and uncertainty about how MPAL fits into established paradigms for treatment of acute leukemia. The purpose of this review is to explain the diagnostic criteria for MPAL, summarize its biological and clinical features, and address common diagnostic pitfalls of these unusual leukemias.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2017 |
---|---|
Erschienen: |
2017 |
Enthalten in: |
Zur Gesamtaufnahme - volume:141 |
---|---|
Enthalten in: |
Archives of pathology & laboratory medicine - 141(2017), 11 vom: 20. Nov., Seite 1462-1468 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Charles, Nathan J [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 06.11.2017 Date Revised 08.04.2022 published: Print Citation Status MEDLINE |
---|
doi: |
10.5858/arpa.2017-0218-RA |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM277408636 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM277408636 | ||
003 | DE-627 | ||
005 | 20231225014136.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2017 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.5858/arpa.2017-0218-RA |2 doi | |
028 | 5 | 2 | |a pubmed24n0924.xml |
035 | |a (DE-627)NLM277408636 | ||
035 | |a (NLM)29072953 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Charles, Nathan J |e verfasserin |4 aut | |
245 | 1 | 0 | |a Mixed-Phenotype Acute Leukemia |b Diagnostic Criteria and Pitfalls |
264 | 1 | |c 2017 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 06.11.2017 | ||
500 | |a Date Revised 08.04.2022 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Mixed-phenotype acute leukemia (MPAL) is a heterogeneous category in the World Health Organization classification that comprises acute leukemias with discrete admixed populations of myeloid and lymphoid blasts ("bilineal") or with extensive coexpression of lymphoid and myeloid markers in a single blast population ("biphenotypic"). Flow cytometric findings suggestive of MPAL are often met with consternation by pathologists and oncologists alike, owing to unfamiliarity with the disease and uncertainty about how MPAL fits into established paradigms for treatment of acute leukemia. The purpose of this review is to explain the diagnostic criteria for MPAL, summarize its biological and clinical features, and address common diagnostic pitfalls of these unusual leukemias | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
650 | 7 | |a BCR-ABL1 fusion protein, human |2 NLM | |
650 | 7 | |a Biomarkers, Tumor |2 NLM | |
650 | 7 | |a KMT2A protein, human |2 NLM | |
650 | 7 | |a Myeloid-Lymphoid Leukemia Protein |2 NLM | |
650 | 7 | |a 149025-06-9 |2 NLM | |
650 | 7 | |a Histone-Lysine N-Methyltransferase |2 NLM | |
650 | 7 | |a EC 2.1.1.43 |2 NLM | |
650 | 7 | |a Fusion Proteins, bcr-abl |2 NLM | |
650 | 7 | |a EC 2.7.10.2 |2 NLM | |
700 | 1 | |a Boyer, Daniel F |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Archives of pathology & laboratory medicine |d 1978 |g 141(2017), 11 vom: 20. Nov., Seite 1462-1468 |w (DE-627)NLM000037508 |x 1543-2165 |7 nnns |
773 | 1 | 8 | |g volume:141 |g year:2017 |g number:11 |g day:20 |g month:11 |g pages:1462-1468 |
856 | 4 | 0 | |u http://dx.doi.org/10.5858/arpa.2017-0218-RA |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 141 |j 2017 |e 11 |b 20 |c 11 |h 1462-1468 |